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In this Q&A, we talk to Professor Yehuda Shoenfeld about Autoimmune Syndrome Induced by Adjuvants (ASIA)
and discuss his recommendations regarding further research in the field.Introduction
Professor Yehuda Shoenfeld is the founder and head of
the Zabludowicz Center for Autoimmune Diseases at the
Sheba Medical Center, which is affiliated to the Sackler
Faculty of Medicine at Tel-Aviv University, Israel. He is
also the Incumbent of the Laura Schwarz-Kipp Chair for
Research of Autoimmune Diseases at Tel-Aviv University.
His clinical and scientific works focus on autoimmune and
rheumatic diseases, and he has been the recipient of
multiple awards, including a Life Contribution Prize in
Internal Medicine in Israel, 2012.
In recent years, Professor Shoenfeld noted that four
conditions: siliconosis, Gulf War syndrome (GWS),
macrophagicmyofasciitis syndrome (MMF) and post-
vaccination phenomena were linked with previous expos-
ure to an adjuvant, and that the patients also presented
with similar clinical symptoms. In 2011, this led Professor
Shoenfeld to suggest these comparable conditions should
be grouped under a common syndrome entitled ‘ASIA’, for
‘Autoimmune (Autoinflammatory) Syndrome Induced by
Adjuvants’.
In this Q&A we talk to Professor Shoenfeld about
ASIA, and discuss his recommendations regarding fur-
ther research in the field.What is ASIA?
ASIA is a new syndrome, which refers to autoimmune
syndromes induced by adjuvants. It includes several con-
ditions that are not fully characterized as autoimmune
diseases like systemic lupus, rheumatoid arthritis or
scleroderma, but that are induced by chronic stimulationCorrespondence: shoenfel@post.tau.ac.il
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reproduction in any medium, provided the orof the immune system by substances which may react as
adjuvants. This chronic stimulation leads to the emer-
gence of these new signs and symptoms, which include
fatigue, arthritis, myalgia, and neurological manifestations.
Which adjuvants commonly used in medical practice have
been implicated in ASIA?
The idea of ASIA as a new syndrome developed after
some studies on Gulf War syndrome reported that sol-
diers who had not been deployed to the Gulf area were
suffering from symptoms such as severe fatigue, cogni-
tive impairment, myalgias and arthralgias. This raised
the question of whether it was the vaccines administered
to the soldiers that induced these syndromes. The most
common adjuvants are silicone implants and aluminum
in vaccines.
Are any other adjuvants associated with ASIA?
There are some specific adjuvants which have been
shown to induce ASIA; for instance, aluminium. Alu-
minium is the oldest, the cheapest and the most efficient
adjuvant so far, which is why it is still commonly used in
the development of vaccines.
In 2001, Romain Gherardi and colleagues reported that
patients diagnosed with macrophagic myofasciitis, or
MMF (a rare muscle disease characterized by specific
myopathological alterations, first described by the Groupe
d’Etudes et Recherche sur les Maladies Musculaires
Acquises et Dysimmunitaires (GERMMAD)), had previ-
ously been vaccinated with hepatitis vaccines containing
aluminium hydroxide. These patients went on to develop
severe myalgia with neurological manifestations, cognitive
impairment, dizziness, inability to concentrate and poor
sleep. Following many studies, Romain Gherardi and col-
leagues were able to demonstrate that the aluminium isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from the muscles to different organs and penetrates the
blood-brain barrier. On this basis, MMF is part of the
ASIA syndrome.
Another condition termed the ‘sick building syndrome’
(SBS) leads to similar clinical symptoms as the Gulf War
syndrome, and manifests in people living in a specific
room or building. However, once they move to another
room or to another building, they completely recover. It
is believed that, in that room, there is some substance
that reacts or behaves like the adjuvant. I have already
mentioned that aluminium is used as an adjuvant in vac-
cines, but as one of the most common materials in the
world its uses are even more widespread, as much of the
equipment we use in our daily lives is made from
aluminium.
As the use of vaccines, silicone implants, etc., is
widespread, what does this mean in terms of public
health?
First of all, vaccines are very widespread, and I would
like to clarify that I am definitely not against vaccines!
Vaccines are the best medical development that human-
kind has had in the last 300 years, and have helped to
bring about almost complete eradication of some viral
diseases. However, it should be considered that when
you give millions of people an active substance, and vac-
cines are active substances, then some may suffer from
adverse events. After all, vaccines contain viral or syn-
thetic particles emulsified in adjuvant, which is supposed
to enhance the immune reaction.
So, we have to identify the people who are at risk of
suffering from side effects due to the chronic stimulation
of their immune system. First of all we have to diagnose
them, to treat them—and some of them should be com-
pensated, because the vaccines are quite often imposed
on them either by the state, the government, or by the
employer.
With regard to silicone implants, which is a very com-
mon cosmetic operation, there have been claims that the
silicone is completely inert, that it doesn’t leak and travel
through the body, that it doesn’t induce granulomas,
etc., but this is misleading. There have been recent cases
of ruptured silicone implants, but even with unruptured
implants, there are nanoparticles of silicone that can
travel through the body. Therefore silicone can be found
in different parts, such as the hands, the chest and the
groin. Although silicone implants are quite common,
luckily enough the syndrome itself is rare.
Similarly, autoimmune diseases which are definitely in-
duced by infections are not as common as the infections
themselves. This is because a specific interaction be-
tween the infective agent and the genetic components is
linked to incidence of autoimmune diseases.With regard to the ASIA syndrome, prevalence is
higher in subjects that carry the gene HLA-DRB1. It
should be noted that this is the same HLA (human
leukocyte antigen) which was found to be present in
those who had developed an autoimmune disease fol-
lowing vaccine administration. So, maybe in the future
with further advances in personalized medicine, we will be
able to screen those at risk based on their genetic compos-
ition, and therefore avoid onset of autoimmune diseases
by avoiding administration of vaccines containing adju-
vants that are known to be associated with the ASIA syn-
drome. In test subjects the type of adjuvant can be
replaced with one that might not be associated with the
ASIA syndrome. I would like to emphasize that currently
there are novel adjuvants in development which have to be
tested for efficacy, but we hope these might have fewer side
effects than aluminium and other established adjuvants.What are the current criteria used for diagnosis of ASIA?
We have published the criteria and classified it as we do
usually with different autoimmune diseases, namely into
major criteria and minor criteria. Major criteria include
clinical manifestations such as severe fatigue, poor sleep,
myalgia and arthralgia; the minor criteria include the pres-
ence of various autoantibodies and specific HLA (e.g.,
DRB1). However, as I mentioned before, over the years
many of these patients may go on to develop a more well-
defined autoimmune disease. For instance, if they develop
scleroderma or systemic sclerosis, they will suffer from tight
skin, complications of the lungs, kidneys, and so forth.Have the mechanisms via which adjuvants may cause
these effects been established?
In part, the mechanism involves the chronic stimulation
of the immune system, which may then lead to the re-
lease of inflammatory cytokines including interferon γ,
interferon α, interleukin (IL)-1, IL-6, tumor necrosis fac-
tor (TNF)α and so forth. So in part, this syndrome can
be induced by this cascade of cytokines released in re-
sponse to the chronic stimulation.
This chronic stimulation may also involve the opening
of the blood-brain barrier, and therefore penetration of
different substances into the brain. For example, one of
the mechanisms which has been well defined is that alu-
minium deposits in the body following vaccine injection,
or following exposure to other sources of aluminium,
and these particles can cross the blood-brain barrier via
macrophages and deposit in the brain.
In the past, we physicians witnessed this aluminium
‘toxicity’ of the brain in cases where the patient went
through dialysis. The dialysate fluid contained alumin-
ium, and actually diffused into the brain through the
blood-brain barrier leading to aluminium intoxication.
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consistent with the ASIA syndrome.
In addition, chronic stimulation also induces different
autoantibodies. Although the autoantibodies do not neces-
sarily indicate a specific autoimmune disease, it might be a
combination of anti-DNA antibody which is more classic
for systemic lupus erythematosus (SLE), but also anti-
mitochondrial antibodies which may indicate primary
biliary cirrhosis. As I mentioned earlier, the undefined
connective tissue diseases (UCTD) over the years may de-
velop to a specific autoimmune disease. Therefore we also
believe that most cases of UCTD are actually part of ASIA
syndrome.Is there any evidence to suggest that environmental or
genetic factors may lead to higher risk of developing ASIA?
The actual prevalence of environmental factors, in
addition to silicone implants and the adjuvants in the vac-
cine, is not yet known. But based on my experience and
from reading the literature, I can assume that aluminium
and other different materials used in daily life may be
associated. For instance, in the 1980s a significant increase
in lupus cases was observed in an ex-industrial town in
the United States: East Ferry Street in Buffalo, New York.
Following investigations it was found that the area was
heavily contaminated with toxic materials (including lead,
polychlorinated biphenyls, trichloroethylene and volatile
organic compounds).
So, looking at this from a wider context I would say
that it can be considered that toxic materials which can
act like the adjuvants may underlie what we call ‘idio-
pathic’ autoimmune diseases.What is known about the prevalence of ASIA, particularly
in terms of geographical distribution?
There is no knowledge about geographical distribution.
We do know that many of the autoimmune diseases are
more prevalent in populations that live further away
from the equator. It is believed that limited exposure to
sun, and therefore the lack of production of vitamin D,
may be associated with ASIA. We know that vitamin D
is associated with many autoimmune diseases. For in-
stance, in one study we analyzed more than 40 different
autoimmune diseases, and found the patients had signifi-
cantly lower levels of vitamin D in comparison with the
healthy population within the same geographical area.
Studies have emerged from the Philippines, Mexico,
from all over the world, but these are just small series of
cases. There are no large epidemiological studies so far
that have been able to analyze the geographical distribu-
tion. However, I believe that eventually we will find a
correlation between the ASIA syndrome and geograph-
ical distribution.One study from Finland reported a large increase in
cases of narcolepsy, which is now recognized as an auto-
immune condition. The researchers correlated this increase
of narcolepsy incidences with the vaccines which were ad-
ministered during the H1N1 (swine flu) epidemic in that
region. I would like to emphasize that this disease is rec-
ognized in Finland and is strictly associated with the
(HLA) DQB1*0602 genotype. When the vaccine was deliv-
ered during the H1N1 epidemic, there was a 13-fold
increase of narcolepsy in this geographical area. So the
geographic distribution in this case was not connected to
the substance, but rather to the genotype of the people
who live in the area, which made them more susceptible
to developing narcolepsy.What do you think are the future directions of research
into this field?
Efforts should be made to understand the mechanisms
behind ASIA and to develop better adjuvants, especially
in vaccines. After all, numerous people are vaccinated regu-
larly, and we should minimize any potential side effects.
We should learn from ASIA to better understand the
etiology of other autoimmune diseases that are currently
regarded as ‘idiopathic’ (which means that we are idiots
as we don’t know the pathology and etiology!). I would
like that in the future, I will not see the sentence ‘auto-
immune diseases have an unknown etiology’, because we
are coming closer to better understanding this.
I am still concerned about silicone implants; whether
to recommend these should be explanted or not, as
there is no guarantee of full recovery from the ASIA
syndrome if the silicone implants are explanted. If not,
then the patient is left without the implants and con-
tinue to suffer from the ASIA syndrome. Having said
that however, there are a few cases where explanting led
to a complete recovery of the patient from the ASIA
syndrome. This requires further investigation.
A lot of research is going on all over the world, and I
hope that in the future we’ll be able to better identify
those who are at risk of developing this syndrome, and
to avoid it before they do.What is your advice to clinicians for the management and
treatment of patients with autoimmune disorders?
Should they be routinely screened for ASIA?
As there are no markers for ASIA, we cannot screen for
this. My advice to the clinician is to pay more attention
to the history of the patient, specifically regarding their
vaccine history. In the future, I would like for clinicians to
be able to diagnose the patient early on, and in addition
may help to compensate them if appropriate; after all, these
patients suffer. They were completely healthy until they
were vaccinated and then suddenly developed the disease.
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of serological markers may help to identify the risk factors
such as HLA and familial autoimmune background at a
very early stage. The therapy for ASIA should be the same
therapy as for autoimmune diseases—and until we can
understand it better, maybe clinicians should consider
switching to other biological drugs that have not been as-
sociated with ASIA, rather than continue to use the drugs
that have been.Where can I find out more?
See references [1-28].Additional file
Additional file 1: Professor Yehuda Shoenfeld talks about ASIA
(‘autoimmune syndrome induced by adjuvants’).
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